Living with an autoimmune disease means your body's defense system is attacking your own healthy tissues. For people with conditions like myasthenia gravis or Sjögren's syndrome, finding a treatment that actually lasts is a major hurdle. New data from over 3,500 participants across 24 trials looks closely at how targeting B-cells—a specific type of white blood cell—impacts these conditions.
The findings show that certain B-cell treatments work very well for specific diseases. For example, patients with pemphigus vulgaris and myasthenia gravis saw durable immune responses when treated with rituximab and inebilizumab. In cases of Sjögren's syndrome, combining two different medications performed significantly better than using just one. However, some treatments, like BTK inhibitors, showed quick results that did not last as long.
While some treatments like CAR-T cell therapy show promising results for myasthenia gravis, the data is still early and not definitive. For conditions like rheumatoid arthritis and systemic sclerosis, some treatments improved symptoms but did not lead to full clinical remission. Overall, these therapies were well tolerated by patients, but the results vary depending on the specific disease and the type of B-cell targeting used.
